Neuroinflammation in Progressive Supranuclear Palsy

Neuroinflammation in Progressive Supranuclear Palsy

Overview

Neuroinflammation is a critical pathological feature of Progressive Supranuclear Palsy (PSP), though its role differs from other neurodegenerative tauopathies. In PSP, neuroinflammatory responses are characterized by distinct microglial activation patterns, unique cytokine profiles, and regional specificity that correlates with tau pathology burden [1][2]. Understanding these neuroimmune differences provides insights into disease mechanisms and identifies potential therapeutic targets for modification.

The neuroinflammatory landscape in PSP involves:

• Microglial activation predominantly in basal ganglia and brainstem regions
• Astrocytic responses distinct from those seen in Alzheimer's disease
• Complement system involvement in tau pathology propagation
• Peripheral immune interactions that may contribute to disease progression

Microglial Activation Patterns in PSP

Regional Distribution

Microglial activation in PSP shows a characteristic regional distribution that mirrors the pattern of tau pathology:

| Brain Region | Microglial Activation Level | Correlation with Tau |
|--------------|---------------------------|---------------------|
| Globus pallidus | Very high | Strong |
| Subthalamic nucleus | High | Strong |
| Substantia nigra | High | Moderate |
| Brainstem nuclei | High | Moderate |
| Cerebellar dentate nucleus | Moderate-High | Moderate |
| Cerebral cortex | Low-Moderate | Weak |

...

Neuroinflammation in Progressive Supranuclear Palsy

Overview

Neuroinflammation is a critical pathological feature of Progressive Supranuclear Palsy (PSP), though its role differs from other neurodegenerative tauopathies. In PSP, neuroinflammatory responses are characterized by distinct microglial activation patterns, unique cytokine profiles, and regional specificity that correlates with tau pathology burden [1][2]. Understanding these neuroimmune differences provides insights into disease mechanisms and identifies potential therapeutic targets for modification.

The neuroinflammatory landscape in PSP involves:

• Microglial activation predominantly in basal ganglia and brainstem regions
• Astrocytic responses distinct from those seen in Alzheimer's disease
• Complement system involvement in tau pathology propagation
• Peripheral immune interactions that may contribute to disease progression

Microglial Activation Patterns in PSP

Regional Distribution

Microglial activation in PSP shows a characteristic regional distribution that mirrors the pattern of tau pathology:

| Brain Region | Microglial Activation Level | Correlation with Tau |
|--------------|---------------------------|---------------------|
| Globus pallidus | Very high | Strong |
| Subthalamic nucleus | High | Strong |
| Substantia nigra | High | Moderate |
| Brainstem nuclei | High | Moderate |
| Cerebellar dentate nucleus | Moderate-High | Moderate |
| Cerebral cortex | Low-Moderate | Weak |

The basal ganglia, particularly the [globus pallidus](/cell-types/globus-pallidus-neurons-progressive-supranuclear-palsy) and [subthalamic nucleus](/cell-types/subthalamic-nucleus-psp), show the most pronounced microglial activation in PSP [3]. This contrasts with Alzheimer's disease, where microglial activation is most prominent in cortical regions, and with corticobasal degeneration, where activation is more asymmetric and cortical.

Activation Phenotype

Microglia in PSP predominantly exhibit an M1-like pro-inflammatory phenotype, characterized by:

• Increased expression of pro-inflammatory cytokines: IL-1β, IL-6, TNF-α
• Elevated MHC class II expression: Indicating antigen presentation capability
• Reactive morphology: Amoeboid shape with shortened processes
• TSPO overexpression: Visualized via PET imaging

This M1 predominance differs from corticobasal degeneration, where a mixed M1/M2 phenotype is observed, and from Alzheimer's disease, where disease-associated microglia (DAM) or microglia-neurodegeneration (MGnD) phenotypes are prominent [4].

TSPO-PET Imaging Findings

Translocator protein (TSPO) positron emission tomography (PET) provides in vivo evidence of neuroinflammation in PSP:

Key Findings

Elevated TSPO binding in PSP brains compared to healthy controls

Regional specificity: Highest binding in globus pallidus, subthalamic nucleus, and substantia nigra

Correlation with disease severity: Higher binding correlates with worse clinical scores

Progressive increases: Binding increases over disease duration

Comparison with Other Tauopathies

| Disease | TSPO Binding Pattern | Relative Intensity |
|---------|---------------------|-------------------|
| PSP | Basal ganglia > brainstem > cortex | High |
| CBD | Asymmetric cortical > basal ganglia | Moderate-High |
| AD | Cortical > hippocampus | Moderate |
| PD | Substantia nigra > basal ganglia | Low-Moderate |

These imaging findings confirm that neuroinflammation in PSP has a distinct anatomical distribution that aligns with the characteristic tau pathology pattern [5].

TREM2 Genetics in PSP

Background

TREM2 (Triggering Receptor Expressed on Myeloid Cells 2) is a receptor expressed on microglia that plays a critical role in microglial homeostasis and phagocytosis. Rare variants in TREM2 increase Alzheimer's disease risk substantially [6].

TREM2 in PSP

The role of TREM2 in PSP differs from Alzheimer's disease:

Variant frequency: TREM2 rare variants are less frequent in PSP than in AD

Risk effect: Some variants show modest risk association but weaker than in AD

Functional studies: Microglial TREM2 expression is altered in PSP but less dramatically than in AD

Therapeutic implications: TREM2-targeting therapies developed for AD may have limited efficacy in PSP

The weaker TREM2 association in PSP suggests that microglial dysfunction in PSP may occur through different pathways than in AD, potentially related to tau-driven microglial activation rather than amyloid-driven mechanisms [7].

Cytokine and Biomarker Profiles

Pro-inflammatory Cytokines

Elevated levels of pro-inflammatory cytokines are detected in PSP:

• IL-1β: Elevated in CSF and blood
• IL-6: Increased in both compartments
• TNF-α: Elevated in advanced disease
• IFN-γ: Associated with disease progression

Neuroinflammatory Biomarkers

| Biomarker | PSP Change | Clinical Relevance |
|-----------|------------|-------------------|
| YKL-40 | Elevated | Disease progression marker |
| sTREM2 | Variable | Reflects microglial activation |
| Neurofilament light chain (NfL) | Elevated | Disease severity |
| Tau (total and phosphorylated) | Elevated | Pathology burden |

YKL-40, a chitinase-3-like protein produced by activated microglia and astrocytes, shows particular promise as a biomarker in PSP, correlating with disease severity and progression [8].

Comparison with Other Tauopathies

PSP vs Alzheimer's Disease

• Spatial pattern: PSP shows basal ganglia/brainstem predilection vs cortical/hippocampal in AD
• Microglial phenotype: PSP shows M1 predominance vs DAM/MGnD in AD
• TREM2 involvement: Weaker in PSP than AD
• Astrocytic response: Different astrocyte phenotypes between diseases

PSP vs Corticobasal Degeneration

• Distribution: PSP more symmetric, CBD more asymmetric
• Cortical involvement: CBD shows more cortical inflammation
• Phenotype: CBD shows mixed M1/M2, PSP shows M1 predominance
• Temporal pattern: CBD may show inflammation preceding tau pathology

PSP vs Multiple System Atrophy

• Primary pathology: PSP is tauopathy, MSA is α-synucleinopathy
• Oligodendroglial involvement: More prominent in MSA
• Microglial patterns: Different regional distributions
• Inflammatory response: MSA shows distinct cytokine profile

Astrocytic Involvement

Astrocytes in PSP exhibit distinctive changes:

Reactive Astrocytosis

• GFAP upregulation: Marked increase in affected regions
• Morphological changes: Hypertrophic processes
• Regional distribution: Matches tau pathology distribution
• Functional implications: Both protective and pathological roles

Astrocyte-Neuron Interactions

• glutamate dysregulation: Altered glutamate transporter expression
• Potassium buffering: Impaired potassium homeostasis
• Blood-brain barrier interactions: Modified barrier function
• Tau propagation: Potential role in spreading tau pathology

Complement System Involvement

The complement system is increasingly recognized in PSP pathogenesis:

Key Components

• C1q: Initiates classical complement cascade
• C3/C3a: Pro-inflammatory mediator
• C5a: Anaphylatoxin with neurotoxic effects

Role in Tau Pathology

Complement proteins may contribute to tau pathology through:

• Microglial pruning of tau-affected synapses
• Opsonization of tau aggregates for phagocytosis
• Inflammatory amplification loops
• Synaptic dysfunction via complement-mediated processes

Therapeutic Implications

Anti-inflammatory Approaches

Minocycline: Mixed results in clinical trials

NSAIDs: No clear benefit in PSP

Corticosteroids: Limited efficacy

Microglia-Targeted Therapies

CSF1R antagonists: Reduce microglial proliferation

TREM2 modulators: Less relevant given weaker PSP association

NLRP3 inhibitors: Target inflammasome activation

Neuroprotective Strategies

Reduction of neuroinflammation may slow progression

Combination approaches targeting both tau and inflammation

Early intervention before extensive damage occurs

Cross-Links to Related Mechanisms

• [Mitochondrial Complex I Dysfunction in PSP](/mechanisms/psp-mitochondrial-complex-i) — mitochondrial dysfunction and neuroinflammation are interconnected
• [Iron Accumulation in PSP](/mechanisms/iron-accumulation-psp) — iron promotes microglial activation
• [Tau Aggregate Specificity in PSP](/mechanisms/psp-tau-aggregate-specificity) — tau pathology drives inflammatory responses
• [Brainstem Circuit Vulnerability in PSP](/mechanisms/brainstem-circuit-vulnerability-psp) — brainstem inflammation contributes to circuit dysfunction
• [Microglia in Neurodegeneration](/cell-types/microglia-neurodegeneration-alzheimer) — general microglial mechanisms
• [Neuroinflammation Pathway](/mechanisms/neuroinflammation-pathway) — general neuroinflammation mechanisms
• [4R Tauopathy Mechanisms](/mechanisms/4r-tauopathy-mechanisms) — shared 4R tauopathy features

Key Genes and Proteins

| Gene/Protein | Role in PSP Neuroinflammation |
|--------------|------------------------------|
| TREM2 | Microglial receptor, risk gene |
| TYROBP (DAP12) | TREM2 signaling adaptor |
| CSF1R | Microglial proliferation factor |
| IL1B | Pro-inflammatory cytokine |
| IL6 | Pro-inflammatory cytokine |
| TNF | Pro-inflammatory cytokine |
| CHI3L1 (YKL-40) | Microglial activation marker |
| GFAP | Astrocyte activation marker |
| C1Q | Complement component |
| C3 | Complement component |

See Also

• [Progressive Supranuclear Palsy Pathway](/mechanisms/psp-pathway)
• [PSP Disease Page](/diseases/progressive-supranuclear-palsy)
• [Nigral Microglia in PSP](/cell-types/nigral-microglia-psp)
• [Neuroimmune Biomarkers in PSP](/biomarkers/neuroimmune-psp-biomarkers)
• [CBS Neuroinflammation](/mechanisms/cbs-neuroinflammation)
• [CBD Neuroinflammation](/mechanisms/cbd-neuroinflammation)

Recent Research Findings (2024-2025)

CSF Cytokine Profiles

Yang et al. (2024) characterized CSF cytokine profiles in PSP vs other tauopathies [9]:

| Cytokine | PSP | CBD | AD | Clinical Correlation |
|----------|-----|-----|-----|---------------------|
| IL-1β | Elevated | Elevated | High | Disease severity |
| IL-6 | Moderate | Moderate | High | Progression rate |
| TNF-α | Elevated | Elevated | Moderate | Cognitive decline |
| YKL-40 | High | High | Moderate | Brain atrophy |

• Distinct profiles: PSP shows unique cytokine pattern different from CBD and AD
• Biomarker potential: Cytokine combinations discriminate PSP from other tauopathies
• Therapeutic monitoring: CSF cytokines may predict treatment response

Emerging Therapeutic Approaches

Recent developments in neuroinflammation-targeted therapies for PSP:

Microglial modulation: CSF1R antagonists reducing microglial proliferation

TREM2 agonists: Activating beneficial microglial functions

Complement inhibitors: Targeting C1q and C3 for tau pathology

Anti-inflammatory drugs: Repurposed NSAIDs showing limited efficacy

Combination approaches: Anti-tau plus anti-inflammatory modalities

References

[Gerhard et al., Microglial activation in PSP measured with TSPO PET](https://pubmed.ncbi.nlm.nih.gov/14517969/)

[Pelkmans et al., Neuroinflammation in 4R tauopathies](https://pubmed.ncbi.nlm.nih.gov/32847652/)

[Togo et al., Microglial activation in PSP](https://pubmed.ncbi.nlm.nih.gov/11835684/)

[Sanchez et al., Disease-associated microglia in tauopathies](https://pubmed.ncbi.nlm.nih.gov/34079125/)

[Hamelin et al., TSPO PET imaging in PSP](https://pubmed.ncbi.nlm.nih.gov/26597511/)

[Guerreiro et al., TREM2 variants in Alzheimer's disease](https://doi.org/10.1056/NEJMoa1211851)

[Bemiller et al., TREM2 deficiency in tauopathy models](https://pubmed.ncbi.nlm.nih.gov/28539458/)

[Jessen et al., YKL-40 in PSP and CBD](https://pubmed.ncbi.nlm.nih.gov/25632048/)

[Yang et al., Cytokine profiles in PSP cerebrospinal fluid](https://doi.org/10.1007/s00401-024-02678-y)